Goldman Sachs has initiated coverage of Vera Therapeutics (NASDAQ:VERA) with a buy rating, citing the potential of its drug candidate atacicept and a recent pullback in the stock. The investment ...

Goldman Sachs analyst Paul Choi initiated coverage of Vera Therapeutics (VERA) with a Buy rating and $58 price target Following the recent ...

The Goldman Sachs Group started coverage on shares of Vera Therapeutics (NASDAQ:VERA – Free Report) in a research note issued to investors on Tuesday morning, Marketbeat reports. The firm issued ...

according to strategists at Goldman Sachs Group Inc. The funding spread — a measure of demand for long exposure through equity derivatives such as swaps, options and futures — has tumbled to ...